Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Minerva Neurosciences Inc
NERV | US
8.00
USD1.99
33.11%
NERV | US
About Minerva Neurosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
8.00
Open
6.02
High
8.15
Low
6.00
Minerva Neurosciences Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia currently submitted an New Drug Application (NDA); and MIN-301 a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop sell and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals Inc. and changed its name to Minerva Neurosciences Inc. in 2013. Minerva Neurosciences Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessNERV | US
Risk
146.3
Sharpe
2.24
Luna's Score
66/100
Recommendation
Buy
Luna says (NERV | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
177.2%1 month
146.3%3 months
107.5%6 months
225.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
11.21
Price to book
2.68
Debt to equity
-1.95
Debt to assets
1.87
Ent. to EBITDA
2.60
Ent. to rev.
0.03
PEG
-
Other Fundamentals
EBITDA
-26.21M
MarketCap
55.95M
MarketCap(USD)
55.95M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-675.09
Short ratio
0.93
Short perc.
0.24
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.13
Range1M
3.44
Range3M
4.64
Volumes: Market Activity
Rel. volume
3.47
Price X volume
4.70M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.60 | 0.53 | Expensive |
| Ent. to Revenue | 0.03 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.68 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 107.53 | 72.80 | Riskier |
| Debt to Equity | -1.95 | -1.23 | Cheaper |
| Debt to Assets | 1.87 | 0.25 | Expensive |
| Market Cap | 55.95M | 3.66B | Emerging |
